Compare · HELP vs NVO
HELP vs NVO
Side-by-side comparison of Cybin Inc. (HELP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HELP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 987.1x HELP ($193.6M).
- Over the past year, HELP is down 53.2% and NVO is down 44.9% - NVO leads by 8.3 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 3 for HELP).
- NVO has more recent analyst coverage (25 ratings vs 2 for HELP).
- Company
- Cybin Inc.
- Novo Nordisk A/S
- Price
- $4.04+4.13%
- $43.40+1.43%
- Market cap
- $193.6M
- $191.15B
- 1M return
- -20.34%
- -7.70%
- 1Y return
- -53.24%
- -44.91%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 8
- Recent ratings
- 2
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HELP
- Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
- SEC Form 6-K filed by Cybin Inc.
- Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
- SEC Form 6-K filed by Cybin Inc.
- SEC Form 6-K filed by Cybin Inc.
- Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
- SEC Form 6-K filed by Cybin Inc.
- Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
- SEC Form 6-K filed by Cybin Inc.
- Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care